Nasal high-mobility group box 1 and caspase in bronchiolitis

Area of Science:

• Pediatric respiratory infections
• Biomarker discovery
• Clinical diagnostics

Background:

• Bronchiolitis is a common pediatric respiratory illness.
• Objective assessment of bronchiolitis severity is challenging.
• Nasal biomarkers may offer objective clinical assessment tools.

Purpose of the Study:

• To investigate differences in nasal caspase and high-mobility group box 1 protein (HMGB1) levels between hospitalized and discharged bronchiolitis patients.
• To evaluate HMGB1 as a potential biomarker for bronchiolitis severity.

Main Methods:

• Observational cross-sectional study of 85 infants (<24 months) with acute bronchiolitis.
• Nasal caspase and HMGB1 levels were measured.
• Clinical severity assessed using the modified respiratory index score (RIS).

Main Results:

• Hospitalized patients had significantly higher nasal HMGB1 levels (2.4-fold increase) compared to discharged patients.
• No significant difference in nasal caspase levels was observed between groups.
• HMGB1 demonstrated better predictive performance for hospitalization (AUC 0.7021) than RIS (AUC 0.5709).

Conclusions:

• Nasal HMGB1 levels can significantly differentiate hospitalized from discharged pediatric patients with bronchiolitis.
• This exploratory study suggests HMGB1's potential for severity stratification in acute bronchiolitis.
• Further research is warranted to validate HMGB1 as a clinical tool for bronchiolitis management.